Happy Friday everyone,

We've made it through another week, and another onslaught of healthcare news. I'm Allison DeAngelis, and I'll lead you through the takeaways:

If you're new to this newsletter, sign up here.

Do you have comments or tips about biotech and pharmaceutical companies? You can email me at adeangelis@insider.com or tweet @ADeAngelis_bio. I will also accept your favorite memes from this Suez Canal situation.

Suez canal ever given
The Ever Given, trapped in the Suez Canal.
Suez Canal Authority

Now, let's dig in (pun intended).

fauci vaccine timeline
Dr. Anthony Fauci.
Reuters, Al Drago/AFP via Getty Images

COVID vaccines under the microscope

If I never hear the word "unprecedented" again, I'll be very happy. But for now, we're still dealing with the pandemic.

Even drug giant AstraZeneca was put under the microscope this week, when the US National Institute of Allergy and Infectious Disease released an usual late-night statement saying that the 79% efficacy rate AstraZeneca had reported for its vaccine may have been based on outdated data.

Read the full story here >>

AstraZeneca revises down its vaccine efficacy in a huge US trial, to 76% from 79%, following concerns from Fauci and other experts that the results were outdated

Moncef Slaoui
Dr. Moncef Slaoui, chief adviser to Operation Warp Speed.
AP Photo/Evan Vucci

Biotechs cut ties with Moncef Slaoui

This week, Andrew Dunn and I covered the fallout from a "substantiated" allegation that Moncef Slaoui sexually harassed a female employee during his time at GlaxoSmithKline.

Slaoui left GSK in 2017, later becoming the head of President Donald Trump's COVID vaccine effort, Operation Warp Speed. He also joined several biotech boards and a startup, Centessa, all of which distanced themselves from Slaoui after the allegation surfaced.

Read the full story here >>

Moncef Slaoui is retreating from the biotech industry after facing a substantiated sexual-harassment claim

masayoshi son softbank
Deep Nishar
Reuters/Issei Kato

SoftBank turns to Deep Nishar and biotech bets

Megan Hernbroth published an exclusive look at how SoftBank's Deep Nishar diligently vets healthcare and biotech investments, resulting in some of the highest returns on investments across the firm. The pressure is on for Nishar, and his cohort of biotechnology and life sciences portfolio companies, after a series of public investment catastrophes like WeWork and failed pizza robot maker Zume, she reported.

Check out the full story here >>

Biotech founders are turning to Deep Nishar as a must-have investor. The SoftBank exec explains the strategy behind his winning bets.

- Allison

Read the original article on Business Insider